title: Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies.
abstract: OBJECTIVE
  AT-rich interactive domain 1A (ARID1A) has recently been identified as a novel tumor suppressor in various tumor types. This study was designed to explore the clinical relevance and prognostic impact of ARID1A expression loss in colorectal cancer (CRC) and gastric cancer (GC).
  
  
  METHODS
  Immunohistochemistry for ARID1A was performed using tissue microarray blocks containing 196 CRCs and 275 GCs, along with paired normal mucosa. Data on clinicopathologic variables and oncologic outcomes of patients were collected and analyzed.
  
  
  RESULTS
  We identified 6.1% (12/196) CRC and 8.0% (22/275) GC cases showing loss of ARID1A expression. Expression of ARID1A in paired mucosal epithelial cells was normal in all patients. Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (p = 0.003) in CRC, with large tumor size (p = 0.037) in GC, and with expanding tumor border in both tumor types (CRC, p = 0.010; GC, p = 0.031). However, no association was evident between ARID1A expression and 5-year overall survival in both tumor types.
  
  
  CONCLUSIONS
  Loss of ARID1A expression is uncommon and not associated with oncologic outcome but may be related to less invasive clinicopathologic features in CRC and GC. Further studies with a larger number of subjects are needed to establish the possible prognostic impact of ARID1A expression loss.
authors.affiliation: Department of Surgery, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Lee
authors.forename: Duck-Woo
authors.initials: DW
authors.lastname: Kim
authors.forename: Hye Seung
authors.initials: HS
authors.lastname: Lee
authors.forename: Myong Hoon
authors.initials: MH
authors.lastname: Ihn
authors.forename: Heung-Kwon
authors.initials: HK
authors.lastname: Oh
authors.forename: Do Joong
authors.initials: DJ
authors.lastname: Park
authors.forename: Hyung-Ho
authors.initials: HH
authors.lastname: Kim
authors.forename: Sung-Bum
authors.initials: SB
authors.lastname: Kang
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007124:Immunoenzyme Techniques; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000378:metabolism*; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: C112476:ARID1A protein, human; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D014157:Transcription Factors